Someone else's clock has started running against them: the company is being paid to solve a problem that is already cost
The model's full reasoning — Q1 2017 call → NOWe need to answer YES or NO based on the transcript. The question asks whether management describes counterparties already losing something real and ongoing, and that this is visible in their behavior. We need to see if there's a running meter on the other side and counterparties acting like it. Let's analyze the transcript. The company is Ionis Pharmaceuticals. They discuss SPINRAZA, volanesorsen, IONIS-TTRRx, etc. The question is about counterparties: customers, partners, etc. Key points: They mention patients with SMA, FCS, etc. But the question is about counterparties losing something real and ongoing. For example, patients with SMA are suffering, but that's not a business counterparty in the sense of a customer paying? Actually, patients are the end users. The paying counterparties are insurers, patients, etc. But the question specifically asks about "counterparties" such as customers, partners, or other counterparties. In the transcript, they talk about Biogen, Novartis, Bayer, and other partners. Are these partners losing something while they wait? For example, Biogen is selling SPINRAZA and earning revenue. They are not losing. The patients are losing health, but that's a different kind of loss. The question focuses on the counterparty's clock running: e.g., a customer whose own operations suffer until the company delivers. Here, the company provides therapies. The patients are the ones suffering, but the patients are not the direct counterparty in a commercial transaction? They are the ultimate beneficiaries. However, the question says "counterparty" broadly, but the examples are about business situations: buyers, partners, etc. The transcript talks about patients with FCS, SMA, etc. But management describes the suffering of patients, but is that a "running meter" on the other side? The loss is health, life, etc. But is that visible in behavior? They might be seeking treatment, but management doesn't describe patients acting urgently in a way that shows they are losing something. The question requires management to describe counterparties "already acting like the meter is running" — e.g., pressing for earlier delivery, paying more, etc. In the transcript, they talk about Biogen's sales, but Biogen is not losing anything. They talk about Novartis partnership and Bayer payments. For Bayer, they paid $75 million to advance both drugs.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
SYM · Q3 2022 → YESThe question is: Does management describe that ITS COUNTERPARTIES ARE ALREADY LOSING SOMETHING REAL AND ONGOING — money, output, access, standing, time, or an opportunity of their own — FOR AS LONG AS...YES The transcript shows management describing customers' ongoing pain from labor shortages and broken supply chains that prevent them from handling demand, with customers actively clamoring for faster deployments and wanting the system as quickly as possible.
CRL · Q2 2022 → YESThe question is whether management describes that their counterparties are already losing something real and ongoing — money, output, access, standing, time, or an opportunity — for as long as they do...
GTES · Q4 2021 → YESThe question is: Does management describe that ITS COUNTERPARTIES ARE ALREADY LOSING SOMETHING REAL AND ONGOING — money, output, access, standing, time, or an opportunity of their own — FOR AS LONG AS...